Lawood & Co’s AbbVie ABBV Stock Holding History

Lawood & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.02M	Buy	12,003 +100	+0.8%	+$21.5K	2.05%	13
2026 Q1	$2.59M	Sell	11,903 -652	-5%	-$145K	2.4%	13
2025 Q4	$2.87M	Buy	+12,555	New	+$2.86M	2.72%	10

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Lawood & Co's ABBV Position: Q2 2026 in Review

Lawood & Co increased its AbbVie (ABBV) stake by 0.84% in Q2 2026, buying an estimated $21.5K and bringing the position to 12,003 shares worth $3.02M. The position accounts for 2.05% of the portfolio, ranked #13.

Lawood & Co first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,207 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Lawood & Co held 12,003 shares of AbbVie worth $3.02M as of Q2 2026.
Lawood & Co bought 100 AbbVie shares in Q2 2026, an estimated $21.5K.
AbbVie made up 2.05% of Lawood & Co's portfolio in Q2 2026, its #13 holding.
Lawood & Co first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,207 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Lawood & Co's 13F filing for Q2 2026, filed 13 Jul 2026.